News | October 08, 2008

RT, New Treatment Raise Survival Rates in Esophageal Cancer Patients

October 9, 2008 - A new therapeutic treatment, when delivered endoscopically and used in combination with chemotherapy and radiation therapy, improved survival rates in patients with locally advanced esophageal cancer, according to a study released at the 73rd Annual Scientific Meeting of the American College of Gastroenterology.

A Phase 2 multi-center study on the safety and long-term efficacy of a new biologic therapy called TNFerade, an injection of an anti-tumor agent, was conducted in 24 patients with locally advanced esophageal cancer.

Patients received standard care chemotherapy and radiation plus TNFerade injection directly into the esophageal tumor through an endoscope or an ultrasound-guided endoscope. TNFerade contains a non-replicating virus, which has been engineered to deliver the gene for a cancer fighting protein, TNF-alpha and works synergistically with chemoradiation representing a "triple threat" to cancer cells.

After a total of five treatments of TNFerade and surgery, researchers found most tumors were of the adenocarcinoma type. TNFerade in combination with chemoradiation in this group of patients, resulted in a median survival of 48.4 months, in contrast to previously published trials showing a median survival of 9.7 to 34 months. At 48 months, three patients had tumor resections, which showed no residual cancer cells in the surgical specimens.

Kenneth Chang, M.D., University of California Irvine Medical Center, where he and his colleagues conducted the study, noted, “TNFerade is a promising treatment that represents a new paradigm in esophageal cancer treatment, with the gastroenterologist administering the local anti-tumor agent through a scope."

For more information: www.acg.gi.org

Related Content

Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Videos | Treatment Planning | August 28, 2018
A discussion with...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...
Radiation Therapy Affects Event Recall for Children With Brain Tumors
News | Radiation Therapy | August 24, 2018
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of...
Videos | Radiation Therapy | August 13, 2018
ITN Editor Dave Fornell takes a tour of some of the innovative new technologies on the expo floor at the 2018 America
Videos | Radiation Therapy | August 13, 2018
A discussion with Mahadevappa Mahesh, MS, Ph.D., FAAPM, FACR, FACMP, FSCCT, professor of radiology and cardiology and
Overlay Init